Stem definition | Drug id | CAS RN |
---|---|---|
peroxisome proliferator activating receptor-gamma (PPAR-gamma) agonists, thiazolidinedione derivatives | 2179 | 111025-46-8 |
Dose | Unit | Route |
---|---|---|
30 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.80 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 83 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
July 15, 1999 | FDA | TAKEDA PHARMS USA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bladder cancer | 542.11 | 12.17 | 158 | 22194 | 4652 | 56265063 |
Hypoglycaemia | 436.10 | 12.17 | 273 | 22079 | 55542 | 56214173 |
Blood glucose increased | 403.12 | 12.17 | 291 | 22061 | 74860 | 56194855 |
Cardiac failure congestive | 181.51 | 12.17 | 198 | 22154 | 87522 | 56182193 |
Glycosylated haemoglobin increased | 136.03 | 12.17 | 73 | 22279 | 11092 | 56258623 |
Diabetes mellitus inadequate control | 133.80 | 12.17 | 78 | 22274 | 13902 | 56255813 |
Blood glucose decreased | 123.36 | 12.17 | 83 | 22269 | 19004 | 56250711 |
Diabetic ketoacidosis | 117.05 | 12.17 | 80 | 22272 | 18791 | 56250924 |
Oedema peripheral | 109.20 | 12.17 | 222 | 22130 | 171032 | 56098683 |
Rheumatoid arthritis | 82.17 | 12.17 | 25 | 22327 | 382579 | 55887136 |
Diabetic metabolic decompensation | 79.56 | 12.17 | 28 | 22324 | 1520 | 56268195 |
Cardiac failure | 78.51 | 12.17 | 127 | 22225 | 81966 | 56187749 |
Pancreatitis | 68.56 | 12.17 | 87 | 22265 | 44993 | 56224722 |
Lactic acidosis | 68.20 | 12.17 | 77 | 22275 | 35269 | 56234446 |
Diabetes mellitus | 60.83 | 12.17 | 89 | 22263 | 52646 | 56217069 |
Drug ineffective | 60.65 | 12.17 | 177 | 22175 | 918812 | 55350903 |
Hyperglycaemia | 59.99 | 12.17 | 75 | 22277 | 38206 | 56231509 |
Myocardial infarction | 59.81 | 12.17 | 121 | 22231 | 92749 | 56176966 |
Systemic lupus erythematosus | 59.10 | 12.17 | 3 | 22349 | 180075 | 56089640 |
Drug intolerance | 57.35 | 12.17 | 17 | 22335 | 264801 | 56004914 |
Oedema | 56.68 | 12.17 | 110 | 22242 | 81810 | 56187905 |
Bladder neoplasm | 56.57 | 12.17 | 17 | 22335 | 556 | 56269159 |
Weight increased | 55.82 | 12.17 | 209 | 22143 | 229494 | 56040221 |
Off label use | 53.20 | 12.17 | 87 | 22265 | 556093 | 55713622 |
Bladder transitional cell carcinoma | 50.81 | 12.17 | 16 | 22336 | 613 | 56269102 |
Macular oedema | 49.58 | 12.17 | 26 | 22326 | 3768 | 56265947 |
Glossodynia | 48.60 | 12.17 | 3 | 22349 | 152455 | 56117260 |
Infusion related reaction | 47.87 | 12.17 | 12 | 22340 | 208919 | 56060796 |
Maternal exposure during pregnancy | 47.25 | 12.17 | 9 | 22343 | 189544 | 56080171 |
Pancreatitis acute | 45.53 | 12.17 | 53 | 22299 | 25071 | 56244644 |
Treatment failure | 44.86 | 12.17 | 7 | 22345 | 170385 | 56099330 |
Contraindicated product administered | 44.05 | 12.17 | 10 | 22342 | 186276 | 56083439 |
Weight decreased | 43.50 | 12.17 | 200 | 22152 | 240514 | 56029201 |
Acute kidney injury | 42.73 | 12.17 | 199 | 22153 | 240564 | 56029151 |
Coronary artery disease | 41.48 | 12.17 | 56 | 22296 | 30740 | 56238975 |
Pancreatic carcinoma | 38.62 | 12.17 | 28 | 22324 | 7213 | 56262502 |
Arthropathy | 36.38 | 12.17 | 17 | 22335 | 200258 | 56069457 |
Wound | 35.86 | 12.17 | 6 | 22346 | 138798 | 56130917 |
Diabetic retinopathy | 33.99 | 12.17 | 17 | 22335 | 2232 | 56267483 |
Lower respiratory tract infection | 31.89 | 12.17 | 4 | 22348 | 114790 | 56154925 |
Alopecia | 31.79 | 12.17 | 42 | 22310 | 293416 | 55976299 |
Ureteric cancer | 31.16 | 12.17 | 7 | 22345 | 69 | 56269646 |
Discomfort | 30.84 | 12.17 | 9 | 22343 | 141752 | 56127963 |
Product complaint | 30.49 | 12.17 | 30 | 22322 | 11730 | 56257985 |
Hypoglycaemic coma | 30.30 | 12.17 | 16 | 22336 | 2351 | 56267364 |
Therapeutic product effect decreased | 29.83 | 12.17 | 15 | 22337 | 169437 | 56100278 |
Renal failure | 28.85 | 12.17 | 103 | 22249 | 110397 | 56159318 |
Chest pain | 28.05 | 12.17 | 149 | 22203 | 189648 | 56080067 |
Joint swelling | 27.93 | 12.17 | 45 | 22307 | 289755 | 55979960 |
Product use issue | 27.81 | 12.17 | 20 | 22332 | 186021 | 56083694 |
Bladder trabeculation | 27.20 | 12.17 | 6 | 22346 | 54 | 56269661 |
Bladder adenocarcinoma stage unspecified | 26.99 | 12.17 | 5 | 22347 | 16 | 56269699 |
Blood glucose fluctuation | 26.13 | 12.17 | 18 | 22334 | 4277 | 56265438 |
Asthenia | 25.35 | 12.17 | 227 | 22125 | 342746 | 55926969 |
Myalgia | 24.77 | 12.17 | 111 | 22241 | 131914 | 56137801 |
Angina unstable | 24.73 | 12.17 | 21 | 22331 | 6800 | 56262915 |
Biopsy skin abnormal | 24.21 | 12.17 | 6 | 22346 | 93 | 56269622 |
Pericarditis | 23.53 | 12.17 | 7 | 22345 | 108916 | 56160799 |
Fall | 23.12 | 12.17 | 230 | 22122 | 357280 | 55912435 |
Therapeutic product effect incomplete | 22.57 | 12.17 | 7 | 22345 | 106024 | 56163691 |
Cholelithiasis | 22.56 | 12.17 | 49 | 22303 | 39415 | 56230300 |
Pancreatitis chronic | 22.47 | 12.17 | 13 | 22339 | 2281 | 56267434 |
Portal fibrosis | 22.26 | 12.17 | 7 | 22345 | 267 | 56269448 |
General physical health deterioration | 22.03 | 12.17 | 21 | 22331 | 169989 | 56099726 |
Blood triglycerides increased | 21.77 | 12.17 | 25 | 22327 | 11652 | 56258063 |
Dehydration | 21.65 | 12.17 | 122 | 22230 | 158703 | 56111012 |
Abdominal discomfort | 21.51 | 12.17 | 49 | 22303 | 277225 | 55992490 |
Exposure during pregnancy | 21.24 | 12.17 | 14 | 22338 | 136328 | 56133387 |
Diabetic neuropathy | 21.15 | 12.17 | 15 | 22337 | 3733 | 56265982 |
Dyspnoea | 20.70 | 12.17 | 340 | 22012 | 592237 | 55677478 |
Radius fracture | 20.57 | 12.17 | 14 | 22338 | 3261 | 56266454 |
Musculoskeletal stiffness | 20.53 | 12.17 | 19 | 22333 | 155988 | 56113727 |
Fasting | 20.34 | 12.17 | 4 | 22348 | 19 | 56269696 |
Fluid retention | 20.15 | 12.17 | 57 | 22295 | 54021 | 56215694 |
Ketoacidosis | 20.02 | 12.17 | 15 | 22337 | 4060 | 56265655 |
Haematuria | 19.58 | 12.17 | 37 | 22315 | 26950 | 56242765 |
Tibia fracture | 18.11 | 12.17 | 15 | 22337 | 4693 | 56265022 |
Nasopharyngitis | 18.00 | 12.17 | 38 | 22314 | 220921 | 56048794 |
Acute myocardial infarction | 17.67 | 12.17 | 38 | 22314 | 30355 | 56239360 |
Pancreatic carcinoma metastatic | 17.58 | 12.17 | 11 | 22341 | 2224 | 56267491 |
High density lipoprotein decreased | 17.30 | 12.17 | 10 | 22342 | 1752 | 56267963 |
Incorrect dose administered | 17.30 | 12.17 | 53 | 22299 | 52494 | 56217221 |
Ketosis | 17.09 | 12.17 | 7 | 22345 | 577 | 56269138 |
Vomiting | 17.05 | 12.17 | 285 | 22067 | 497943 | 55771772 |
Arteriosclerosis coronary artery | 16.77 | 12.17 | 18 | 22334 | 7787 | 56261928 |
Infection | 16.67 | 12.17 | 34 | 22318 | 200172 | 56069543 |
Transitional cell carcinoma | 16.59 | 12.17 | 7 | 22345 | 621 | 56269094 |
Varicose vein ruptured | 16.52 | 12.17 | 4 | 22348 | 56 | 56269659 |
Nicotinic acid deficiency | 16.32 | 12.17 | 4 | 22348 | 59 | 56269656 |
Rash | 16.20 | 12.17 | 122 | 22230 | 492925 | 55776790 |
Nausea | 16.19 | 12.17 | 407 | 21945 | 763771 | 55505944 |
Decreased appetite | 16.11 | 12.17 | 145 | 22207 | 219086 | 56050629 |
IIIrd nerve paralysis | 16.11 | 12.17 | 7 | 22345 | 668 | 56269047 |
Retinal aneurysm | 15.53 | 12.17 | 5 | 22347 | 206 | 56269509 |
Rhabdomyolysis | 15.29 | 12.17 | 43 | 22309 | 40615 | 56229100 |
Ankle fracture | 15.15 | 12.17 | 25 | 22327 | 16378 | 56253337 |
Shock | 14.79 | 12.17 | 29 | 22323 | 21699 | 56248016 |
Left ventricular dysfunction | 14.63 | 12.17 | 20 | 22332 | 11103 | 56258612 |
Visual acuity reduced | 14.52 | 12.17 | 28 | 22324 | 20698 | 56249017 |
Renal impairment | 14.48 | 12.17 | 67 | 22285 | 80646 | 56189069 |
Inflammatory bowel disease | 14.48 | 12.17 | 12 | 22340 | 3756 | 56265959 |
Stomatitis | 14.43 | 12.17 | 16 | 22336 | 120794 | 56148921 |
Unresponsive to stimuli | 14.41 | 12.17 | 36 | 22316 | 31689 | 56238026 |
Blood glucose abnormal | 14.37 | 12.17 | 16 | 22336 | 7212 | 56262503 |
Hepatic enzyme increased | 14.35 | 12.17 | 29 | 22323 | 171355 | 56098360 |
Hypersensitivity | 14.27 | 12.17 | 53 | 22299 | 256355 | 56013360 |
Euglycaemic diabetic ketoacidosis | 14.05 | 12.17 | 11 | 22341 | 3178 | 56266537 |
Arteriosclerosis | 13.98 | 12.17 | 18 | 22334 | 9435 | 56260280 |
Blood ketone body increased | 13.97 | 12.17 | 5 | 22347 | 285 | 56269430 |
Swelling | 13.71 | 12.17 | 49 | 22303 | 239722 | 56029993 |
Adult failure to thrive | 13.70 | 12.17 | 4 | 22348 | 118 | 56269597 |
Postmortem blood drug level increased | 13.67 | 12.17 | 6 | 22346 | 586 | 56269129 |
Acute coronary syndrome | 13.51 | 12.17 | 18 | 22334 | 9750 | 56259965 |
Upper airway obstruction | 13.49 | 12.17 | 6 | 22346 | 605 | 56269110 |
Product use in unapproved indication | 13.42 | 12.17 | 22 | 22330 | 140800 | 56128915 |
Cerebrovascular accident | 13.34 | 12.17 | 76 | 22276 | 99194 | 56170521 |
Pain | 13.16 | 12.17 | 185 | 22167 | 662999 | 55606716 |
Contraindicated product prescribed | 13.04 | 12.17 | 7 | 22345 | 1063 | 56268652 |
Face oedema | 13.02 | 12.17 | 25 | 22327 | 18427 | 56251288 |
Hyperkalaemia | 12.91 | 12.17 | 47 | 22305 | 50818 | 56218897 |
Salpingo-oophorectomy bilateral | 12.89 | 12.17 | 4 | 22348 | 146 | 56269569 |
Cardiomegaly | 12.47 | 12.17 | 23 | 22329 | 16444 | 56253271 |
Insulin resistance | 12.26 | 12.17 | 6 | 22346 | 751 | 56268964 |
Retinal haemorrhage | 12.22 | 12.17 | 12 | 22340 | 4679 | 56265036 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bladder cancer | 2347.53 | 12.22 | 738 | 24287 | 13987 | 31658332 |
Bladder transitional cell carcinoma | 385.33 | 12.22 | 123 | 24902 | 2423 | 31669896 |
Blood glucose increased | 258.27 | 12.22 | 278 | 24747 | 60805 | 31611514 |
Hypoglycaemia | 231.51 | 12.22 | 241 | 24784 | 50705 | 31621614 |
Cardiac failure congestive | 141.52 | 12.22 | 237 | 24788 | 79150 | 31593169 |
Diabetes mellitus inadequate control | 135.31 | 12.22 | 98 | 24927 | 12643 | 31659676 |
Pancreatitis | 134.07 | 12.22 | 153 | 24872 | 35618 | 31636701 |
Glycosylated haemoglobin increased | 124.34 | 12.22 | 86 | 24939 | 10314 | 31662005 |
Oedema peripheral | 100.89 | 12.22 | 249 | 24776 | 109590 | 31562729 |
Haematuria | 97.14 | 12.22 | 149 | 24876 | 46165 | 31626154 |
Pancreatic carcinoma | 86.44 | 12.22 | 64 | 24961 | 8536 | 31663783 |
Diabetic ketoacidosis | 83.97 | 12.22 | 84 | 24941 | 16821 | 31655498 |
Bladder neoplasm | 82.38 | 12.22 | 33 | 24992 | 1275 | 31671044 |
Blood glucose decreased | 65.70 | 12.22 | 64 | 24961 | 12407 | 31659912 |
Myocardial infarction | 61.39 | 12.22 | 213 | 24812 | 113241 | 31559078 |
Off label use | 59.77 | 12.22 | 115 | 24910 | 347159 | 31325160 |
Transitional cell carcinoma | 59.10 | 12.22 | 30 | 24995 | 2029 | 31670290 |
Macular oedema | 54.48 | 12.22 | 31 | 24994 | 2637 | 31669682 |
Weight increased | 49.50 | 12.22 | 161 | 24864 | 82786 | 31589533 |
Ureteric cancer | 47.89 | 12.22 | 14 | 25011 | 202 | 31672117 |
Toxicity to various agents | 47.53 | 12.22 | 44 | 24981 | 181443 | 31490876 |
Product use in unapproved indication | 45.80 | 12.22 | 11 | 25014 | 99160 | 31573159 |
Malignant spinal cord compression | 43.15 | 12.22 | 12 | 25013 | 143 | 31672176 |
Drug ineffective | 43.11 | 12.22 | 164 | 24861 | 395409 | 31276910 |
Oedema | 42.75 | 12.22 | 100 | 24925 | 42461 | 31629858 |
Hyperglycaemia | 40.29 | 12.22 | 89 | 24936 | 36387 | 31635932 |
Pancreatitis acute | 39.74 | 12.22 | 72 | 24953 | 25528 | 31646791 |
Genital infection fungal | 36.92 | 12.22 | 11 | 25014 | 170 | 31672149 |
Bladder cancer recurrent | 36.78 | 12.22 | 13 | 25012 | 353 | 31671966 |
Coronary artery disease | 36.56 | 12.22 | 99 | 24926 | 45988 | 31626331 |
Bladder cancer stage 0, with cancer in situ | 35.03 | 12.22 | 8 | 25017 | 39 | 31672280 |
Diabetic nephropathy | 34.73 | 12.22 | 21 | 25004 | 2000 | 31670319 |
Diabetes mellitus | 30.39 | 12.22 | 88 | 24937 | 42468 | 31629851 |
Meningitis eosinophilic | 28.82 | 12.22 | 6 | 25019 | 17 | 31672302 |
Pemphigoid | 28.64 | 12.22 | 34 | 24991 | 8237 | 31664082 |
Product complaint | 28.44 | 12.22 | 28 | 24997 | 5496 | 31666823 |
Diabetic retinopathy | 27.83 | 12.22 | 17 | 25008 | 1649 | 31670670 |
Acute myocardial infarction | 27.06 | 12.22 | 95 | 24930 | 50728 | 31621591 |
Death | 26.27 | 12.22 | 172 | 24853 | 360397 | 31311922 |
Gallbladder neoplasm | 25.98 | 12.22 | 6 | 25019 | 31 | 31672288 |
Hypoglycaemic coma | 25.68 | 12.22 | 18 | 25007 | 2203 | 31670116 |
General physical health deterioration | 23.68 | 12.22 | 33 | 24992 | 113402 | 31558917 |
Euglycaemic diabetic ketoacidosis | 23.65 | 12.22 | 19 | 25006 | 2855 | 31669464 |
Diabetic metabolic decompensation | 22.80 | 12.22 | 15 | 25010 | 1654 | 31670665 |
Bladder transitional cell carcinoma stage III | 22.13 | 12.22 | 5 | 25020 | 23 | 31672296 |
Treatment failure | 22.10 | 12.22 | 3 | 25022 | 40789 | 31631530 |
Infectious mononucleosis | 21.33 | 12.22 | 10 | 25015 | 568 | 31671751 |
Bladder papilloma | 21.31 | 12.22 | 5 | 25020 | 28 | 31672291 |
Rheumatoid arthritis | 20.73 | 12.22 | 6 | 25019 | 47803 | 31624516 |
Overdose | 20.43 | 12.22 | 22 | 25003 | 84642 | 31587677 |
Renal cyst | 20.39 | 12.22 | 29 | 24996 | 8387 | 31663932 |
Urethral cancer | 20.24 | 12.22 | 6 | 25019 | 91 | 31672228 |
Pollakiuria | 20.12 | 12.22 | 44 | 24981 | 17858 | 31654461 |
Pleural effusion | 20.01 | 12.22 | 114 | 24911 | 74806 | 31597513 |
Intentional product use issue | 19.96 | 12.22 | 7 | 25018 | 49340 | 31622979 |
Anti-insulin antibody positive | 19.84 | 12.22 | 7 | 25018 | 189 | 31672130 |
Malignant neoplasm of renal pelvis | 19.56 | 12.22 | 5 | 25020 | 42 | 31672277 |
Thrombocytopenia | 19.04 | 12.22 | 54 | 24971 | 142693 | 31529626 |
Weight decreased | 18.82 | 12.22 | 201 | 24824 | 159751 | 31512568 |
Cerebral infarction | 18.81 | 12.22 | 54 | 24971 | 25923 | 31646396 |
Diabetic neuropathy | 18.46 | 12.22 | 19 | 25006 | 3930 | 31668389 |
Urine cytology abnormal | 18.44 | 12.22 | 3 | 25022 | 0 | 31672319 |
Cerebrovascular accident | 18.08 | 12.22 | 116 | 24909 | 79368 | 31592951 |
Cardiac failure | 18.07 | 12.22 | 123 | 24902 | 85830 | 31586489 |
Bladder transitional cell carcinoma stage II | 17.87 | 12.22 | 5 | 25020 | 61 | 31672258 |
Hepatic cancer | 17.68 | 12.22 | 26 | 24999 | 7749 | 31664570 |
Pulmonary oedema | 17.04 | 12.22 | 75 | 24950 | 44427 | 31627892 |
Product use issue | 17.02 | 12.22 | 12 | 25013 | 56747 | 31615572 |
Pyrexia | 16.90 | 12.22 | 156 | 24869 | 303684 | 31368635 |
Blood glucose abnormal | 16.87 | 12.22 | 21 | 25004 | 5342 | 31666977 |
Metastatic carcinoma of the bladder | 16.67 | 12.22 | 6 | 25019 | 172 | 31672147 |
Abnormal weight gain | 16.41 | 12.22 | 10 | 25015 | 966 | 31671353 |
Blood creatine phosphokinase increased | 16.27 | 12.22 | 71 | 24954 | 41903 | 31630416 |
Type 2 diabetes mellitus | 16.23 | 12.22 | 36 | 24989 | 14748 | 31657571 |
Prostate cancer | 15.65 | 12.22 | 65 | 24960 | 37536 | 31634783 |
Drug intolerance | 15.60 | 12.22 | 11 | 25014 | 52022 | 31620297 |
Bladder adenocarcinoma stage unspecified | 15.14 | 12.22 | 3 | 25022 | 6 | 31672313 |
Post-thoracotomy pain syndrome | 15.11 | 12.22 | 4 | 25021 | 39 | 31672280 |
Insulin resistance | 14.77 | 12.22 | 8 | 25017 | 618 | 31671701 |
Neutropenia | 14.68 | 12.22 | 59 | 24966 | 140305 | 31532014 |
Retinal aneurysm | 14.61 | 12.22 | 5 | 25020 | 123 | 31672196 |
Isosporiasis | 14.53 | 12.22 | 5 | 25020 | 125 | 31672194 |
Febrile neutropenia | 14.19 | 12.22 | 49 | 24976 | 121800 | 31550519 |
Loss of consciousness | 14.12 | 12.22 | 107 | 24918 | 77248 | 31595071 |
Sleep talking | 13.81 | 12.22 | 7 | 25018 | 472 | 31671847 |
Angina pectoris | 13.75 | 12.22 | 53 | 24972 | 29588 | 31642731 |
Interstitial lung disease | 13.58 | 12.22 | 89 | 24936 | 61314 | 31611005 |
Intentional overdose | 13.43 | 12.22 | 8 | 25017 | 41381 | 31630938 |
Aortic stenosis | 13.20 | 12.22 | 16 | 25009 | 3960 | 31668359 |
Angina unstable | 13.13 | 12.22 | 28 | 24997 | 11167 | 31661152 |
Hypoglycaemic unconsciousness | 13.09 | 12.22 | 8 | 25017 | 776 | 31671543 |
Urogenital infection fungal | 13.07 | 12.22 | 3 | 25022 | 15 | 31672304 |
Rectal cancer | 12.93 | 12.22 | 12 | 25013 | 2189 | 31670130 |
Metastases to liver | 12.87 | 12.22 | 30 | 24995 | 12697 | 31659622 |
Cholelithiasis | 12.68 | 12.22 | 39 | 24986 | 19440 | 31652879 |
Blood urine present | 12.61 | 12.22 | 26 | 24999 | 10131 | 31662188 |
Hepatic function abnormal | 12.53 | 12.22 | 65 | 24960 | 41157 | 31631162 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bladder cancer | 2297.35 | 11.30 | 687 | 36833 | 16555 | 70874369 |
Hypoglycaemia | 584.94 | 11.30 | 447 | 37073 | 93917 | 70797007 |
Blood glucose increased | 485.92 | 11.30 | 416 | 37104 | 102566 | 70788358 |
Bladder transitional cell carcinoma | 462.43 | 11.30 | 129 | 37391 | 2390 | 70888534 |
Cardiac failure congestive | 248.07 | 11.30 | 331 | 37189 | 135126 | 70755798 |
Diabetes mellitus inadequate control | 241.36 | 11.30 | 150 | 37370 | 22495 | 70868429 |
Diabetic ketoacidosis | 205.32 | 11.30 | 154 | 37366 | 31358 | 70859566 |
Oedema peripheral | 177.50 | 11.30 | 380 | 37140 | 227711 | 70663213 |
Glycosylated haemoglobin increased | 167.33 | 11.30 | 108 | 37412 | 17283 | 70873641 |
Haematuria | 137.73 | 11.30 | 169 | 37351 | 63404 | 70827520 |
Bladder neoplasm | 133.99 | 11.30 | 45 | 37475 | 1580 | 70889344 |
Blood glucose decreased | 131.15 | 11.30 | 106 | 37414 | 24053 | 70866871 |
Myocardial infarction | 113.29 | 11.30 | 268 | 37252 | 171377 | 70719547 |
Pancreatitis | 109.77 | 11.30 | 150 | 37370 | 62518 | 70828406 |
Pancreatic carcinoma | 104.51 | 11.30 | 72 | 37448 | 12832 | 70878092 |
Diabetic metabolic decompensation | 96.50 | 11.30 | 42 | 37478 | 3010 | 70887914 |
Rheumatoid arthritis | 95.80 | 11.30 | 19 | 37501 | 291786 | 70599138 |
Off label use | 92.73 | 11.30 | 157 | 37363 | 742903 | 70148021 |
Drug ineffective | 91.59 | 11.30 | 229 | 37291 | 939523 | 69951401 |
Hyperglycaemia | 84.67 | 11.30 | 135 | 37385 | 64537 | 70826387 |
Macular oedema | 83.85 | 11.30 | 45 | 37475 | 5117 | 70885807 |
Ureteric cancer | 81.62 | 11.30 | 21 | 37499 | 281 | 70890643 |
Cardiac failure | 78.78 | 11.30 | 209 | 37311 | 143332 | 70747592 |
Oedema | 78.59 | 11.30 | 171 | 37349 | 103410 | 70787514 |
Weight increased | 76.94 | 11.30 | 292 | 37228 | 242039 | 70648885 |
Transitional cell carcinoma | 72.84 | 11.30 | 32 | 37488 | 2345 | 70888579 |
Diabetes mellitus | 68.02 | 11.30 | 130 | 37390 | 71694 | 70819230 |
Coronary artery disease | 64.97 | 11.30 | 118 | 37402 | 62618 | 70828306 |
Drug intolerance | 62.02 | 11.30 | 21 | 37499 | 225666 | 70665258 |
Diabetic retinopathy | 60.77 | 11.30 | 30 | 37490 | 2867 | 70888057 |
Drug abuse | 54.10 | 11.30 | 7 | 37513 | 147249 | 70743675 |
Acute myocardial infarction | 53.76 | 11.30 | 119 | 37401 | 72768 | 70818156 |
Pancreatitis acute | 53.23 | 11.30 | 90 | 37430 | 45134 | 70845790 |
Hypoglycaemic coma | 51.86 | 11.30 | 31 | 37489 | 4330 | 70886594 |
Treatment failure | 50.27 | 11.30 | 8 | 37512 | 144134 | 70746790 |
Malignant spinal cord compression | 47.92 | 11.30 | 12 | 37508 | 143 | 70890781 |
Infusion related reaction | 46.77 | 11.30 | 23 | 37497 | 197511 | 70693413 |
Bladder cancer stage 0, with cancer in situ | 46.61 | 11.30 | 10 | 37510 | 56 | 70890868 |
Pemphigoid | 43.56 | 11.30 | 45 | 37475 | 13977 | 70876947 |
Lactic acidosis | 43.33 | 11.30 | 102 | 37418 | 64922 | 70826002 |
Bladder cancer recurrent | 41.97 | 11.30 | 14 | 37506 | 481 | 70890443 |
Genital infection fungal | 41.28 | 11.30 | 11 | 37509 | 170 | 70890754 |
Product use in unapproved indication | 40.93 | 11.30 | 30 | 37490 | 207448 | 70683476 |
Euglycaemic diabetic ketoacidosis | 40.54 | 11.30 | 30 | 37490 | 5977 | 70884947 |
Bladder adenocarcinoma stage unspecified | 39.91 | 11.30 | 8 | 37512 | 30 | 70890894 |
Diabetic nephropathy | 39.05 | 11.30 | 22 | 37498 | 2751 | 70888173 |
General physical health deterioration | 37.19 | 11.30 | 42 | 37478 | 235989 | 70654935 |
Maternal exposure during pregnancy | 36.80 | 11.30 | 8 | 37512 | 115337 | 70775587 |
Rhabdomyolysis | 35.08 | 11.30 | 121 | 37399 | 95639 | 70795285 |
Diabetic neuropathy | 34.56 | 11.30 | 27 | 37493 | 5831 | 70885093 |
Contraindicated product administered | 34.48 | 11.30 | 14 | 37506 | 134598 | 70756326 |
Angina unstable | 33.98 | 11.30 | 42 | 37478 | 15851 | 70875073 |
Lower respiratory tract infection | 33.28 | 11.30 | 9 | 37511 | 111904 | 70779020 |
Toxicity to various agents | 31.91 | 11.30 | 100 | 37420 | 382072 | 70508852 |
Product use issue | 31.78 | 11.30 | 29 | 37491 | 179908 | 70711016 |
Cerebrovascular accident | 31.66 | 11.30 | 155 | 37365 | 143315 | 70747609 |
Bladder papilloma | 31.48 | 11.30 | 6 | 37514 | 16 | 70890908 |
Pleural effusion | 31.10 | 11.30 | 146 | 37374 | 132718 | 70758206 |
Pulmonary oedema | 31.04 | 11.30 | 105 | 37415 | 82173 | 70808751 |
Chest pain | 30.84 | 11.30 | 233 | 37287 | 251027 | 70639897 |
Urine cytology abnormal | 30.38 | 11.30 | 5 | 37515 | 3 | 70890921 |
Cerebral infarction | 30.34 | 11.30 | 69 | 37451 | 42940 | 70847984 |
Glossodynia | 29.70 | 11.30 | 5 | 37515 | 86482 | 70804442 |
Weight decreased | 29.61 | 11.30 | 272 | 37248 | 310216 | 70580708 |
Retinal aneurysm | 29.08 | 11.30 | 9 | 37511 | 242 | 70890682 |
Blood creatine phosphokinase increased | 27.50 | 11.30 | 83 | 37437 | 61180 | 70829744 |
Dehydration | 27.35 | 11.30 | 209 | 37311 | 225933 | 70664991 |
Pericarditis | 26.76 | 11.30 | 6 | 37514 | 84699 | 70806225 |
Retinal haemorrhage | 26.25 | 11.30 | 26 | 37494 | 7684 | 70883240 |
Exposure during pregnancy | 26.18 | 11.30 | 7 | 37513 | 87710 | 70803214 |
Meningitis eosinophilic | 25.80 | 11.30 | 5 | 37515 | 15 | 70890909 |
Product complaint | 25.63 | 11.30 | 32 | 37488 | 12199 | 70878725 |
Intentional product use issue | 25.52 | 11.30 | 16 | 37504 | 120126 | 70770798 |
Bladder trabeculation | 25.10 | 11.30 | 6 | 37514 | 58 | 70890866 |
Urethral cancer | 24.74 | 11.30 | 6 | 37514 | 62 | 70890862 |
Alopecia | 23.66 | 11.30 | 43 | 37477 | 198447 | 70692477 |
Bladder transitional cell carcinoma stage III | 23.62 | 11.30 | 5 | 37515 | 26 | 70890898 |
Hypersensitivity | 23.00 | 11.30 | 55 | 37465 | 229757 | 70661167 |
Gallbladder neoplasm | 23.00 | 11.30 | 6 | 37514 | 85 | 70890839 |
Blood triglycerides increased | 22.95 | 11.30 | 39 | 37481 | 19625 | 70871299 |
Renal failure | 22.44 | 11.30 | 174 | 37346 | 188896 | 70702028 |
Fluid retention | 22.26 | 11.30 | 79 | 37441 | 63306 | 70827618 |
Visual acuity reduced | 22.18 | 11.30 | 47 | 37473 | 27883 | 70863041 |
Ketoacidosis | 21.99 | 11.30 | 23 | 37497 | 7246 | 70883678 |
Prostate cancer | 21.98 | 11.30 | 50 | 37470 | 31113 | 70859811 |
Pain | 21.44 | 11.30 | 221 | 37299 | 628595 | 70262329 |
Hepatic cancer | 21.37 | 11.30 | 26 | 37494 | 9657 | 70881267 |
Wound | 21.17 | 11.30 | 13 | 37507 | 98719 | 70792205 |
Cholelithiasis | 21.12 | 11.30 | 64 | 37456 | 47276 | 70843648 |
Discomfort | 21.10 | 11.30 | 15 | 37505 | 105421 | 70785503 |
Blood glucose fluctuation | 21.09 | 11.30 | 21 | 37499 | 6246 | 70884678 |
Insulin resistance | 20.72 | 11.30 | 11 | 37509 | 1223 | 70889701 |
Joint swelling | 20.59 | 11.30 | 67 | 37453 | 253144 | 70637780 |
Arthropathy | 20.22 | 11.30 | 30 | 37490 | 150027 | 70740897 |
Blood glucose abnormal | 20.02 | 11.30 | 25 | 37495 | 9532 | 70881392 |
Hepatic function abnormal | 19.95 | 11.30 | 80 | 37440 | 67916 | 70823008 |
Anti-insulin antibody positive | 19.80 | 11.30 | 7 | 37513 | 287 | 70890637 |
Peripheral swelling | 19.65 | 11.30 | 62 | 37458 | 236501 | 70654423 |
Febrile neutropenia | 19.58 | 11.30 | 50 | 37470 | 204268 | 70686656 |
Therapeutic product effect incomplete | 19.23 | 11.30 | 21 | 37499 | 119861 | 70771063 |
Acute kidney injury | 19.18 | 11.30 | 355 | 37165 | 474269 | 70416655 |
Cardiomegaly | 19.14 | 11.30 | 41 | 37479 | 24504 | 70866420 |
Renal cyst | 19.04 | 11.30 | 29 | 37491 | 13316 | 70877608 |
Lacunar infarction | 19.00 | 11.30 | 19 | 37501 | 5677 | 70885247 |
Coronary artery occlusion | 18.83 | 11.30 | 30 | 37490 | 14315 | 70876609 |
Hydronephrosis | 18.82 | 11.30 | 31 | 37489 | 15211 | 70875713 |
Pyrexia | 18.81 | 11.30 | 218 | 37302 | 606734 | 70284190 |
IIIrd nerve paralysis | 18.70 | 11.30 | 10 | 37510 | 1129 | 70889795 |
Bladder transitional cell carcinoma stage II | 18.66 | 11.30 | 5 | 37515 | 79 | 70890845 |
Biopsy skin abnormal | 18.54 | 11.30 | 6 | 37514 | 187 | 70890737 |
Musculoskeletal stiffness | 18.52 | 11.30 | 31 | 37489 | 147729 | 70743195 |
Angina pectoris | 18.47 | 11.30 | 62 | 37458 | 48321 | 70842603 |
Retinal exudates | 18.44 | 11.30 | 10 | 37510 | 1160 | 70889764 |
High density lipoprotein decreased | 18.08 | 11.30 | 16 | 37504 | 4103 | 70886821 |
Psoriatic arthropathy | 17.82 | 11.30 | 6 | 37514 | 64765 | 70826159 |
Fatigue | 17.53 | 11.30 | 319 | 37201 | 824000 | 70066924 |
Nasopharyngitis | 17.24 | 11.30 | 60 | 37460 | 222146 | 70668778 |
Fall | 17.19 | 11.30 | 330 | 37190 | 443766 | 70447158 |
Rash | 17.15 | 11.30 | 180 | 37340 | 510382 | 70380542 |
Blood ketone body increased | 17.11 | 11.30 | 8 | 37512 | 678 | 70890246 |
Fasting | 17.09 | 11.30 | 4 | 37516 | 35 | 70890889 |
Ill-defined disorder | 17.05 | 11.30 | 4 | 37516 | 54737 | 70836187 |
Pancreatic carcinoma metastatic | 17.02 | 11.30 | 15 | 37505 | 3825 | 70887099 |
Stomatitis | 17.02 | 11.30 | 26 | 37494 | 128485 | 70762439 |
Decreased appetite | 16.79 | 11.30 | 240 | 37280 | 304540 | 70586384 |
Low density lipoprotein increased | 16.74 | 11.30 | 21 | 37499 | 8044 | 70882880 |
Aortic stenosis | 16.65 | 11.30 | 19 | 37501 | 6597 | 70884327 |
Ketosis | 16.51 | 11.30 | 9 | 37511 | 1055 | 70889869 |
Malignant neoplasm of renal pelvis | 16.50 | 11.30 | 5 | 37515 | 125 | 70890799 |
Arthralgia | 16.29 | 11.30 | 179 | 37341 | 503211 | 70387713 |
Diabetic retinal oedema | 15.95 | 11.30 | 7 | 37513 | 512 | 70890412 |
Blood urea increased | 15.93 | 11.30 | 57 | 37463 | 45852 | 70845072 |
Transient ischaemic attack | 15.91 | 11.30 | 57 | 37463 | 45887 | 70845037 |
Diabetic complication | 15.49 | 11.30 | 9 | 37511 | 1192 | 70889732 |
Renal cell carcinoma | 15.35 | 11.30 | 19 | 37501 | 7182 | 70883742 |
Pancreatitis chronic | 15.33 | 11.30 | 14 | 37506 | 3740 | 70887184 |
Death | 15.10 | 11.30 | 185 | 37335 | 509876 | 70381048 |
Microalbuminuria | 15.06 | 11.30 | 8 | 37512 | 891 | 70890033 |
Portal fibrosis | 15.04 | 11.30 | 7 | 37513 | 587 | 70890337 |
Radius fracture | 14.97 | 11.30 | 13 | 37507 | 3253 | 70887671 |
Isosporiasis | 14.90 | 11.30 | 5 | 37515 | 175 | 70890749 |
Face oedema | 14.72 | 11.30 | 38 | 37482 | 25601 | 70865323 |
Hypoglycaemic encephalopathy | 14.67 | 11.30 | 7 | 37513 | 621 | 70890303 |
Cardiac failure acute | 14.55 | 11.30 | 30 | 37490 | 17457 | 70873467 |
Peripheral vascular disorder | 14.47 | 11.30 | 19 | 37501 | 7613 | 70883311 |
Mucosal inflammation | 14.45 | 11.30 | 9 | 37511 | 67841 | 70823083 |
Metastatic carcinoma of the bladder | 14.43 | 11.30 | 5 | 37515 | 193 | 70890731 |
Abnormal weight gain | 14.41 | 11.30 | 11 | 37509 | 2295 | 70888629 |
Multiple injuries | 14.41 | 11.30 | 13 | 37507 | 3418 | 70887506 |
Cardiac disorder | 14.41 | 11.30 | 66 | 37454 | 59349 | 70831575 |
Urogenital infection fungal | 14.27 | 11.30 | 3 | 37517 | 15 | 70890909 |
Infectious mononucleosis | 13.99 | 11.30 | 10 | 37510 | 1889 | 70889035 |
Helicobacter infection | 13.91 | 11.30 | 6 | 37514 | 55650 | 70835274 |
Chronic gastritis | 13.84 | 11.30 | 13 | 37507 | 3600 | 70887324 |
Treatment noncompliance | 13.82 | 11.30 | 55 | 37465 | 46519 | 70844405 |
Pollakiuria | 13.78 | 11.30 | 44 | 37476 | 33417 | 70857507 |
Blood pressure fluctuation | 13.76 | 11.30 | 7 | 37513 | 59005 | 70831919 |
Therapeutic product effect decreased | 13.70 | 11.30 | 35 | 37485 | 142983 | 70747941 |
Duodenal ulcer perforation | 13.61 | 11.30 | 5 | 37515 | 51107 | 70839817 |
Folliculitis | 13.48 | 11.30 | 3 | 37517 | 42567 | 70848357 |
Adenocarcinoma pancreas | 13.44 | 11.30 | 10 | 37510 | 2008 | 70888916 |
Arteriosclerosis | 13.21 | 11.30 | 28 | 37492 | 16610 | 70874314 |
Varicose vein ruptured | 13.16 | 11.30 | 4 | 37516 | 101 | 70890823 |
Hypoglycaemic unconsciousness | 13.16 | 11.30 | 8 | 37512 | 1152 | 70889772 |
Polydipsia | 13.08 | 11.30 | 16 | 37504 | 5972 | 70884952 |
Rectal cancer | 12.96 | 11.30 | 12 | 37508 | 3262 | 70887662 |
Salpingo-oophorectomy bilateral | 12.95 | 11.30 | 3 | 37517 | 25 | 70890899 |
Sinusitis | 12.91 | 11.30 | 46 | 37474 | 169149 | 70721775 |
Coma | 12.72 | 11.30 | 18 | 37502 | 91826 | 70799098 |
Nocturia | 12.68 | 11.30 | 23 | 37497 | 12181 | 70878743 |
Renal impairment | 12.65 | 11.30 | 124 | 37396 | 143813 | 70747111 |
Urine ketone body present | 12.64 | 11.30 | 12 | 37508 | 3367 | 70887557 |
Infection | 12.57 | 11.30 | 63 | 37457 | 210722 | 70680202 |
Blood creatinine increased | 12.47 | 11.30 | 123 | 37397 | 142878 | 70748046 |
Dilatation atrial | 12.25 | 11.30 | 12 | 37508 | 3500 | 70887424 |
Loss of control of legs | 12.11 | 11.30 | 9 | 37511 | 1805 | 70889119 |
Ventricular hypertrophy | 11.88 | 11.30 | 16 | 37504 | 6568 | 70884356 |
Neuropathic arthropathy | 11.88 | 11.30 | 5 | 37515 | 330 | 70890594 |
Cellulitis | 11.70 | 11.30 | 91 | 37429 | 98837 | 70792087 |
Humerus fracture | 11.66 | 11.30 | 18 | 37502 | 8360 | 70882564 |
Dyspnoea | 11.66 | 11.30 | 508 | 37012 | 769552 | 70121372 |
Neutropenia | 11.57 | 11.30 | 84 | 37436 | 257072 | 70633852 |
Asthenia | 11.45 | 11.30 | 320 | 37200 | 457346 | 70433578 |
Sleep talking | 11.35 | 11.30 | 7 | 37513 | 1034 | 70889890 |
None
Source | Code | Description |
---|---|---|
ATC | A10BD05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD06 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD09 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD12 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BG03 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Thiazolidinediones |
FDA CS | M0199111 | PPAR alpha |
FDA CS | M0199114 | PPAR gamma |
FDA CS | M0447306 | Thiazolidinediones |
FDA MoA | N0000175374 | Peroxisome Proliferator-activated Receptor Activity |
FDA EPC | N0000175596 | Peroxisome Proliferator Receptor alpha Agonist |
MeSH PA | D007004 | Hypoglycemic Agents |
CHEBI has role | CHEBI:35469 | antidepressants |
CHEBI has role | CHEBI:35526 | antidiabetic |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:50864 | insulin sensitizers |
CHEBI has role | CHEBI:71554 | PPARgamma agonist |
CHEBI has role | CHEBI:77194 | ATP:pantothenate 4-phosphotransferase inhibitor |
CHEBI has role | CHEBI:77307 | cardioprotective agents |
CHEBI has role | CHEBI:83157 | EC 6.2.1.3 inhibitors |
CHEBI has role | CHEBI:173084 | ferroptosis inhibitors |
CHEBI has role | CHEBI:176497 | geroprotectors |
FDA EPC | N0000180186 | Peroxisome Proliferator Receptor gamma Agonist |
FDA EPC | N0000180190 | Thiazolidinedione |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Alcoholism | contraindication | 7200002 | |
Asthenia | contraindication | 13791008 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Acute vomiting | contraindication | 23971007 | |
Alcohol intoxication | contraindication | 25702006 | |
Shock | contraindication | 27942005 | |
Dehydration | contraindication | 34095006 | |
Macular retinal edema | contraindication | 37231002 | DOID:4449 |
Infectious disease | contraindication | 40733004 | |
Body fluid retention | contraindication | 43498006 | |
Chronic heart failure | contraindication | 48447003 | |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Ketoacidosis | contraindication | 56051008 | |
Metabolic acidosis | contraindication | 59455009 | |
Hemolytic anemia | contraindication | 61261009 | DOID:583 |
Glucose-6-phosphate dehydrogenase deficiency anemia | contraindication | 62403005 | |
Hypopituitarism | contraindication | 74728003 | DOID:9406 |
Cardiogenic shock | contraindication | 89138009 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Fracture of bone | contraindication | 125605004 | |
Autonomic dysreflexia | contraindication | 129618003 | |
Liver function tests abnormal | contraindication | 166603001 | |
Cobalamin deficiency | contraindication | 190634004 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypoglycemic disorder | contraindication | 237630007 | |
Sepsis syndrome | contraindication | 238150007 | |
Edema | contraindication | 267038008 | |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Fever | contraindication | 386661006 | |
Surgical procedure | contraindication | 387713003 | |
Malignant tumor of urinary bladder | contraindication | 399326009 | DOID:11054 |
Severe diarrhea | contraindication | 409587002 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Traumatic injury | contraindication | 417746004 | |
Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
Radiography with IV Iodinated Contrast Agent | contraindication | ||
Severe Hypoxemia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.33 | acidic |
pKa2 | 7.15 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 12.5MG BASE;EQ 15MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | DISCN | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
EQ 12.5MG BASE;EQ 30MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
EQ 12.5MG BASE;EQ 45MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | DISCN | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
EQ 25MG BASE;EQ 15MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
EQ 25MG BASE;EQ 30MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
EQ 25MG BASE;EQ 45MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
EQ 12.5MG BASE;EQ 15MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | DISCN | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
EQ 12.5MG BASE;EQ 30MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
EQ 12.5MG BASE;EQ 45MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | DISCN | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
EQ 25MG BASE;EQ 15MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
EQ 25MG BASE;EQ 30MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
EQ 25MG BASE;EQ 45MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | AGONIST | EC50 | 6.23 | WOMBAT-PK | CHEMBL | |||
Bile salt export pump | Transporter | IC50 | 6.52 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 6.30 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 4.46 | DRUG MATRIX | |||||
Peroxisome proliferator-activated receptor alpha | Nuclear hormone receptor | EC50 | 5.18 | CHEMBL | |||||
CDGSH iron-sulfur domain-containing protein 1 | Unclassified | Ki | 6.43 | CHEMBL | |||||
Carbonic anhydrase 2 | Enzyme | IC50 | 6.94 | DRUG MATRIX | |||||
CDGSH iron-sulfur domain-containing protein 2 | Unclassified | IC50 | 5.32 | CHEMBL | |||||
Aldose reductase | Enzyme | IC50 | 4.88 | DRUG MATRIX | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.68 | CHEMBL | |||||
Peroxisome proliferator-activated receptor alpha | Transcription factor | IC50 | 5.94 | CHEMBL | |||||
Peroxisome proliferator-activated receptor gamma | Transcription factor | IC50 | 6.15 | CHEMBL | |||||
Peroxisome proliferator-activated receptor gamma | Transcription factor | IC50 | 6.15 | CHEMBL | |||||
Enoyl-[acyl-carrier-protein] reductase [NADH] | Enzyme | IC50 | 4.10 | CHEMBL | |||||
Bile salt export pump | Transporter | IC50 | 5.70 | CHEMBL | |||||
CDGSH iron-sulfur domain-containing protein 1 | Unclassified | IC50 | 6 | CHEMBL |
ID | Source |
---|---|
4021165 | VUID |
N0000148616 | NUI |
D00945 | KEGG_DRUG |
112529-15-4 | SECONDARY_CAS_RN |
4021165 | VANDF |
4021166 | VANDF |
4029214 | VANDF |
C0071097 | UMLSCUI |
CHEBI:8228 | CHEBI |
8N6 | PDB_CHEM_ID |
CHEMBL595 | ChEMBL_ID |
DB01132 | DRUGBANK_ID |
CHEMBL1715 | ChEMBL_ID |
D000077205 | MESH_DESCRIPTOR_UI |
4829 | PUBCHEM_CID |
2694 | IUPHAR_LIGAND_ID |
6343 | INN_ID |
X4OV71U42S | UNII |
259319 | RXNORM |
178611 | MMSL |
29092 | MMSL |
35713 | MMSL |
8258 | MMSL |
d04442 | MMSL |
007823 | NDDF |
007824 | NDDF |
116097005 | SNOMEDCT_US |
326058001 | SNOMEDCT_US |
395828009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7271 | TABLET | 15 mg | ORAL | ANDA | 29 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7271 | TABLET | 15 mg | ORAL | ANDA | 29 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7272 | TABLET | 30 mg | ORAL | ANDA | 29 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7272 | TABLET | 30 mg | ORAL | ANDA | 29 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7273 | TABLET | 45 mg | ORAL | ANDA | 29 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7273 | TABLET | 45 mg | ORAL | ANDA | 29 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5420 | TABLET | 15 mg | ORAL | ANDA | 28 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5421 | TABLET | 30 mg | ORAL | ANDA | 28 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5422 | TABLET | 45 mg | ORAL | ANDA | 28 sections |
Pioglitazone and metformin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-5626 | TABLET, FILM COATED | 15 mg | ORAL | ANDA | 29 sections |
Pioglitazone and metformin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-5627 | TABLET, FILM COATED | 15 mg | ORAL | ANDA | 29 sections |
Pioglitazone hydrochloride and glimepiride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-5634 | TABLET | 30 mg | ORAL | ANDA | 28 sections |
Pioglitazone hydrochloride and glimepiride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-5635 | TABLET | 30 mg | ORAL | ANDA | 28 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7090 | TABLET | 15 mg | ORAL | ANDA | 30 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7090 | TABLET | 15 mg | ORAL | ANDA | 30 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7096 | TABLET | 30 mg | ORAL | ANDA | 30 sections |
Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7096 | TABLET | 30 mg | ORAL | ANDA | 30 sections |
PIOGLITAZONEHYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-119 | TABLET | 30 mg | ORAL | ANDA | 26 sections |
PIOGLITAZONEHYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-120 | TABLET | 45 mg | ORAL | ANDA | 26 sections |
PIOGLITAZONEHYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-140 | TABLET | 15 mg | ORAL | ANDA | 26 sections |
Pioglitazone HCL and Metformin HCL | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-280 | TABLET | 15 mg | ORAL | ANDA | 28 sections |
Pioglitazone HCL and Metformin HCL | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-281 | TABLET | 15 mg | ORAL | ANDA | 28 sections |
Pioglitazone | Human Prescription Drug Label | 1 | 16714-645 | TABLET | 15 mg | ORAL | ANDA | 30 sections |
Pioglitazone | Human Prescription Drug Label | 1 | 16714-646 | TABLET | 30 mg | ORAL | ANDA | 30 sections |
Pioglitazone | Human Prescription Drug Label | 1 | 16714-647 | TABLET | 45 mg | ORAL | ANDA | 30 sections |
PIOGLITAZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-020 | TABLET | 15 mg | ORAL | ANDA | 29 sections |
PIOGLITAZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-021 | TABLET | 30 mg | ORAL | ANDA | 29 sections |
PIOGLITAZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-022 | TABLET | 45 mg | ORAL | ANDA | 29 sections |
Actos | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-147 | TABLET | 15 mg | ORAL | NDA | 31 sections |
Actos | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-148 | TABLET | 30 mg | ORAL | NDA | 31 sections |